• 1
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22: 465475.
  • 2
    Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, Shea B, Tugwell P, Wells G, Osteoporosis Research Advisory Group (ORAG) 2001 A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 12: 140151.
  • 3
    Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group 2002 Meta-analyses of therapies for postmenopausal osteoporosis. III Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23: 517523.
  • 4
    Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group 2002 Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23: 508516.
  • 5
    Torgerson DJ, Bell-Syer SE 2001 Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 285: 28912897.
  • 6
    Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23: 524528.
  • 7
    Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group 2002 Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23: 540551.
  • 8
    Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group 2002 Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23: 560569.
  • 9
    Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Hamel C, Ortiz Z, Peterson J, Adachi J, Tugwell P, Guyatt G, Osteoporosis Methodology Group; Osteoporosis Research Advisory Group 2004 Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev CD004526.
  • 10
    Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B 2005 Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 293: 22572264.
  • 11
    Canalis E, Giustina A, Bilezikian JP 2007 Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357: 905916.
  • 12
    Caplan AI 1991 Mesenchymal stem cells. J Orthop Res 9: 641650.
  • 13
    Gerson SL 1999 Mesenchymal stem cells: No longer second class marrow citizens. Nat Med 5: 262264.
  • 14
    Lee OK, Ko YC, Kuo TK, Chou SH, Li HJ, Chen WM, Chen TH, Su Y 2004 Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells. J Cell Biochem 93: 917928.
  • 15
    Corti S, Locatelli F, Strazzer S, Guglieri M, Comi GP 2003 Neuronal generation from somatic stem cells: Current knowledge and perspectives on the treatment of acquired and degenerative central nervous system disorders. Curr Gene Ther 3: 247272.
  • 16
    Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, Chen JR, Chen YP, Lee OK 2004 In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 40: 12751284.
  • 17
    Chamberlain J, Yamagami T, Colletti E, Theise ND, Desai J, Frias A, Pixley J, Zanjani ED, Porada CD, Almeida-Porada G 2007 Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 46: 19351945.
  • 18
    Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I 2006 The role of mesenchymal stem cells in haemopoiesis. Blood Rev 20: 161171.
  • 19
    Bruder SP, Fink DJ, Caplan AI 1994 Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 56: 283294.
  • 20
    Oreffo RO, Cooper C, Mason C, Clements M 2005 Mesenchymal stem cells: Lineage, plasticity, and skeletal therapeutic potential. Stem Cell Rev 1: 169178.
  • 21
    Anklesaria P, Kase K, Glowacki J, Holland CA, Sakakeeny MA, Wright JA, FitzGerald TJ, Lee CY, Greenberger JS 1987 Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. Proc Natl Acad Sci USA 84: 76817685.
  • 22
    Pereira RF, Halford KW, O'Hara MD, Leeper DB, Sokolov BP, Pollard MD, Bagasra O, Prockop DJ 1995 Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 92: 48574861.
  • 23
    Ding L, Lu S, Batchu R, III RS , Munshi N 1999 Bone marrow stromal cells as a vehicle for gene transfer. Gene Ther 6: 16111616.
  • 24
    Nilsson SK, Dooner MS, Weier HU, Frenkel B, Lian JB, Stein GS, Quesenberry PJ 1999 Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice. J Exp Med 189: 729734.
  • 25
    Hou Z, Nguyen Q, Frenkel B, Nilsson SK, Milne M, van Wijnen AJ, Stein JL, Quesenberry P, Lian JB, Stein GS 1999 Osteoblast-specific gene expression after transplantation of marrow cells: Implications for skeletal gene therapy. Proc Natl Acad Sci USA 96: 72947299.
  • 26
    Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK 1999 Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5: 309313.
  • 27
    Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK 2001 Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97: 12271231.
  • 28
    Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T 2002 Isolated allogeneic bone marrow- derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 99: 89328937.
  • 29
    Zhang XS, Linkhart TA, Chen ST, Peng H, Wergedal JE, Guttierez GG, Sheng MH, Lau KH, Baylink DJ 2004 Local ex vivo gene therapy with bone marrow stromal cells expressing human BMP4 promotes endosteal bone formation in mice. J Gene Med 6: 415.
  • 30
    Papayannopoulou T 2003 Bone marrow homing: The players, the playfield, and their evolving roles. Curr Opin Hematol 10: 214219.
  • 31
    Lapidot T, Kollet O 2002 The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 16: 19922003.
  • 32
    Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, Devine S 2003 Stem cell mobilization. Hematology (Am Soc Hematol Educ Program) XXX: 419437.
  • 33
    Lapidot T, Dar A, Kollet O 2005 How do stem cells find their way home ? Blood 106: 19011910.
  • 34
    Cashman J, Clark-Lewis I, Eaves A, Eaves C 2002 Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. Blood 99: 792799.
  • 35
    Cashman J, Dykstra B, Clark-Lewis I, Eaves A, Eaves C 2002 Changes in the proliferative activity of human hematopoietic stem cells in NOD/SCID mice and enhancement of their transplantability after in vivo treatment with cell cycle inhibitors. J Exp Med 196: 11411149.
  • 36
    Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ, Bellantuono I 2004 A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104: 26432645.
  • 37
    Ji JF, He BP, Dheen ST, Tay SS 2004 Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 22: 415427.
  • 38
    Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A 2006 Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1- CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24: 12541264.
  • 39
    Komori T 2002 Runx2, a multifunctional transcription factor in skeletal development. J Cell Biochem 87: 18.
  • 40
    McLaughlin F, Mackintosh J, Hayes BP, McLaren A, Uings IJ, Salmon P, Humphreys J, Meldrum E, Farrow SN 2002 Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone 30: 924930.
  • 41
    Cristofolini L, Viceconti M, Cappello A, Toni A 1996 Mechanical validation of whole bone composite femur models. J Biomech 29: 525535.
  • 42
    Licata AA 2007 Clinical perspectives on bone quality in osteoporosis: Effects of drug therapy. Drugs Aging 24: 529535.
  • 43
    Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P 2007 Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk-a meta-analysis. Osteoporos Int 18: 4557.
  • 44
    Kumar S, Mahendra G, Nagy TR, Ponnazhagan S 2004 Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Hum Gene Ther 15: 11971206.
  • 45
    Mauney JR, Volloch V, Kaplan DL 2005 Role of adult mesenchymal stem cells in bone tissue engineering applications: Current status and future prospects. Tissue Eng 11: 787802.
  • 46
    Wang Z, Goh J, Das De S, Ge Z, Ouyang H, Chong JS, Low SL, Lee EH 2006 Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng 12: 1753.
  • 47
    Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP 2007 Stem cell transplantation: The lung barrier. Transplant Proc 39: 573576.
  • 48
    Kahn J, Byk T, Jansson-Sjostrand L, Petit I, Shivtiel S, Nagler A, Hardan I, Deutsch V, Gazit Z, Gazit D, Karlsson S, Lapidot T 2004 Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 103: 29422949.
  • 49
    Canalis E 2005 Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep 3: 98102.
  • 50
    O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS 2004 Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145: 18351841.
  • 51
    Shin HH, Kim SJ, Kang SY, Lee DS, Choi HS 2006 Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells. Bone 39: 716723.
  • 52
    Swanson C, Lorentzon M, Conaway HH, Lerner UH 2006 Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 147: 36133622.
  • 53
    Zhu W, Boachie-Adjei O, Rawlins BA, Frenkel B, Boskey AL, Ivashkiv LB, Blobel CP 2007 A novel regulatory role for stromal-derived factor-1 signaling in bone morphogenic protein-2 osteogenic differentiation of mesenchymal C2C12 cells. J Biol Chem 282: 1867618685.
  • 54
    Nuttall ME, Gimble JM 2004 Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4: 290294.
  • 55
    Rosen CJ, Bouxsein ML 2006 Mechanisms of disease: Is osteoporosis the obesity of bone ? Nat Clin Pract Rheumatol 2: 3543.
  • 56
    Bonnaire F, Zenker H, Lill C, Weber AT, Linke B 2005 Treatment strategies for proximal femur fractures in osteoporotic patients. Osteoporos Int 16 (Suppl 2): S93S102.
  • 57
    Miyama K, Yamada G, Yamamoto TS, Takagi C, Miyado K, Sakai M, Ueno N, Shibuya H 1999 A BMP-inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction. Dev Biol 208: 123133.
  • 58
    Tu Q, Valverde P, Li S, Zhang J, Yang P, Chen J 2007 Osterix overexpression in mesenchymal stem cells stimulates healing of critical-sized defects in murine calvarial bone. Tissue Eng 13: 24312440.
  • 59
    Byers BA, Guldberg RE, García AJ 2004 Synergy between genetic and tissue engineering: Runx2 overexpression and in vitro construct development enhance in vivo mineralization. Tissue Eng 10: 17571766.
  • 60
    Lien CY, Lee OK, Su Y 2007 Cbfb enhances the osteognic differentiation of both human and mouse mesenchymal stem cells induced by Cbfa-1 via reducing its ubiquitination- mediated degradation. Stem Cells 25: 1462.
  • 61
    Li CY, Schaffler MB, Wolde-Semait HT, Hernandez CJ, Jepsen KJ 2005 Genetic background influences cortical bone response to ovariectomy. J Bone Miner Res 20: 21502158.